Related Experiment Video
Updated: Apr 16, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
B152 anti-hyperglycosylated human chorionic gonadotropin free β-Subunit. A new, possible treatment for cancer
Objective:
To investigate the ability of B152 to block cancer growth in cell lines in vivo and in nude mice in vitro.
Study Design:
We examined JAR, JEG-3, and NTERA trophoblastic cancer cell lines and KLE, Hec-1A, SCaBER, and T24 nontrophoblastic cancer cell lines. JEG-3 cells were transplanted into 8 nude mice. Four nude mice were administered B152 antibody, and 4 were administered control non-specific IgG. Two studies were completed: first with antibody treatment started 2 weeks after cancer transplantation, and second with antibody treatment started at the time of transplantation.
Results:
In 3 trophoblastic cancer lines and 4 non-trophoblastic cancer cell lines, B152 suppressed the growth of cancer cells, forcing cells into a state of regression. When B152 was administered to nude mice with tumor xenographs, the antibody blocked cancer cell growth and invoked oncostasis. When B152 was administered to nude mice starting at time of xenograph transplantation, the antibody prevented tumor growth completely.
Conclusion:
B152 suppresses tumor growth by seemingly blocking hyperglycosylated human chorionic gonadotropin (hCG) free β-subunit effects. Thus, highly specific antibodies against hCG such as B152 may form part of a novel adjuvant treatment regimen against hCG-producing tumors in humans. This may form a new treatment for humans.
Insights
The B152 antibody effectively blocked cancer cell growth in both cell lines and nude mice models. Early administration of B152 prevented tumor development, suggesting a novel cancer treatment approach.
Area of Science:
- Oncology
- Immunotherapy
- Biotechnology
Background:
- Cancer growth is often driven by specific molecular pathways.
- Targeted antibody therapies offer potential for novel treatment strategies.
- Human chorionic gonadotropin (hCG) is implicated in certain tumor progressions.
Purpose of the Study:
- To evaluate the efficacy of the B152 antibody in inhibiting cancer cell proliferation.
- To assess the anti-cancer effects of B152 in both in vitro and in vivo models.
- To investigate B152's potential as an adjuvant therapy for hCG-producing tumors.
Main Methods:
- Tested B152 against multiple trophoblastic and non-trophoblastic cancer cell lines.
- Utilized a xenograft model in nude mice with JEG-3 cancer cells.
- Administered B152 at different time points relative to tumor transplantation.
Main Results:
- B152 demonstrated significant suppression of cancer cell growth across tested cell lines.
- In vivo studies showed B152 induced oncostasis and blocked tumor xenograft growth.
- Prophylactic administration of B152 completely prevented tumor formation in mice.
Conclusions:
- B152 antibody effectively inhibits cancer growth by targeting hyperglycosylated hCG free β-subunit.
- This antibody shows promise as a novel component of adjuvant therapy for hCG-related cancers.
- B152 represents a potential new therapeutic avenue for human cancer treatment.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy